23Andme

Yahoo Finance • 2 months ago

Independent Board Members Of Penny Stock 23andMe Resign, Call Out CEO Anne Wojcicki For Not 'Actionable Proposal' Despite Ample Time

Independent Board Members Of Penny Stock 23andMe Resign, Call Out CEO Anne Wojcicki For Not 'Actionable Proposal' Despite Ample Time On Tuesday, the independent directors of the Board of 23andMe Holding Co. (NASDAQ:ME) sent a letter to An... Full story

Yahoo Finance • 8 months ago

Billionaires Are Snapping Up Beaten-Down 23andMe Stock. Should You Follow Their Lead?

If you're an individual investor who wants to invest like a billionaire fund manager, I've got good news. Following billionaires is relatively easy because the U.S. Securities and Exchange Commission makes anyone who manages over $100 mill... Full story

Yahoo Finance • 10 months ago

SoftBank-Backed Genetic Testing Invitae's Descent from $7B Valuation to Near-Bankruptcy

Invitae Corporation (NYSE:NVTA), backed by SoftBank Group (OTC:SFTBY) (OTC:SFTBF), is reportedly on the brink of filing for bankruptcy in the coming weeks. The San Francisco-based medical genetics company, grappling with a substantial $1.... Full story

Yahoo Finance • last year

23andMe Reports Second Quarter Fiscal 2024 Financial Results

SOUTH SAN FRANCISCO, Calif., Nov. 08, 2023 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME), a leading human genetics and biopharmaceutical company, reported its financial results for the second quarter of fiscal year 2024 (FY24), wh... Full story

Yahoo Finance • last year

23andMe Launches Total Health™, its Comprehensive, Prevention-Based Health Membership

SOUTH SAN FRANCISCO, Calif., Nov. 07, 2023 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading genetic health and biopharmaceutical company, today launched 23andMe+Total Health, its new, comprehensive prevention-bas... Full story

Yahoo Finance • last year

23andMe Announces Updated Safety and Preliminary Efficacy Data From the Phase 1/2a Study of 23ME-00610, an Investigational Antibody Targeting CD200R1

23andMe presented data from the now completed dose escalation phase, and pharmacokinetic / pharmacodynamic (PK/PD) cohorts at the Society for Immunotherapy of Cancer Annual Meeting 2023 Dosing with 23ME-00610 monotherapy in 28 patients wi... Full story

Yahoo Finance • last year

23andMe Announces Collaboration Extension with a New Data Licensing Agreement with GSK

SOUTH SAN FRANCISCO, Calif., Oct. 30, 2023 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (“23andMe”) today announced a new, non-exclusive data license with GSK plc (LSE/NYSE: GSK) which extends their collaboration and enables GSK... Full story

Yahoo Finance • last year

23andMe to Report FY2024 Second Quarter Financial Results

SOUTH SAN FRANCISCO, Calif., Oct. 25, 2023 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading human genetics and biopharmaceutical company with a mission to help people access, understand, and benefit from the huma... Full story

Yahoo Finance • last year

23andMe Announces Poster Presentations on 23ME-00610, an Investigational Antibody Targeting CD200R1, at The Society for Immunotherapy of Cancer’s (SITC) 2023 Annual Meeting

SOUTH SAN FRANCISCO, Calif., Sept. 27, 2023 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading human genetics and biopharmaceutical company, today announced two poster presentations on 23ME-00610, an investigatio... Full story

Yahoo Finance • last year

23andMe and Sickle Cell 101 Collaborate to Expand Sickle Cell Awareness Program

23andMe will offer its Health + Ancestry Service at no cost for up to 1,000 eligible* participants who are 18 years or older and have African ancestry or ancestry from a region where sickle cell disease is common About one in 13 African A... Full story

Yahoo Finance • last year

23andMe Granted New FDA Clearance to Report Additional BRCA Variants

510(k) clearance will allow 23andMe to report an additional 41 genetic variants in the BRCA1 and BRCA2 genes that increase risk for breast, ovarian, prostate and pancreatic cancer Many of these additional variants occur more often in peop... Full story

Yahoo Finance • last year

23andMe Releases New Report Revealing Genetic Likelihood of Experiencing Panic Attacks

SOUTH SAN FRANCISCO, Calif., June 21, 2023 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading human genetics and biopharmaceutical company, today released a new report as part of the 23andMe+ subscription service o... Full story

Yahoo Finance • last year

10 DNA Stocks Billionaires Are Loading Up On

In this article, we discuss 10 DNA stocks that billionaires love. If you want to skip our detailed analysis of the DNA market, head over to 5 DNA Stocks Billionaires Are Loading Up On. Genomics is the study of a complete set of DNA within... Full story

Yahoo Finance • 2 years ago

New 23andMe survey reveals nine out of ten physicians in the U.S. believe genetics play an important part of a patient’s complete health picture

66 percent of doctors say genetic testing could lead to better outcomes because patients are more proactive about their health after learning about their DNA health profile 34 percent of doctors said they had personally taken a direct-to-... Full story

Yahoo Finance • 2 years ago

23andMe Releases New Report Revealing Likelihood of Developing Lupus

SOUTH SAN FRANCISCO, Calif., May 09, 2023 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading human genetics and biopharmaceutical company, today released a new report on lupus, a chronic autoimmune disease that can... Full story

Yahoo Finance • 2 years ago

23andMe Announces Phase 1 Results from the First-in-Human Phase 1/2a Study of 23ME-00610, an Investigational Antibody Targeting CD200R1

First clinical results to be presented at the AACR Annual Meeting 2023 showed 23ME-00610 demonstrated an acceptable safety and tolerability profile, with favorable pharmacokinetics and peripheral CD200R1 saturation in patients with advance... Full story

Yahoo Finance • 2 years ago

Morehouse School of Medicine, Sickle Cell Foundation of Georgia and 23andMe Launch Sickle Cell Carrier Status Awareness Program

Program aims to increase access to information on sickle cell carrier status, and offer resources to individuals with sickle cell trait and sickle cell disease Expands existing initiatives between 23andMe and Morehouse School of Medicine... Full story

Yahoo Finance • 2 years ago

23andMe Aims To Raise Awareness of Lipoprotein(a), a Little-Known Genetic Risk Factor for Cardiovascular Disease

SOUTH SAN FRANCISCO, Calif., March 24, 2023 (GLOBE NEWSWIRE) -- In support of Lipoprotein(a) Awareness Day, 23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading human genetics and biopharmaceutical company, today announced a collaborati... Full story

Yahoo Finance • 2 years ago

23andMe Announces Presentation of Phase 1 Clinical Data for 23ME-00610, an Investigational Antibody Targeting CD200R1, at the American Association for Cancer Research (AACR) Annual Meeting 2023

SOUTH SAN FRANCISCO, Calif., March 14, 2023 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (23andMe) announced that clinical data from the Phase 1 portion of the Phase 1/2a study of 23ME-00610 has been selected for a poster present... Full story

Yahoo Finance • 2 years ago

23andMe Announces First Patient Dosed for the Phase 2a Portion of its Phase 1/2a Study of 23ME-00610, an Investigational Antibody Targeting CD200R1 in Patients with Advanced Solid Malignancies

SOUTH SAN FRANCISCO, Calif., Feb. 28, 2023 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading human genetics and biopharmaceutical company, with a mission to help people access, understand and benefit from the huma... Full story